Xolair, co-developed and co-promoted by San Francisco-based Genentech and East Hanover, N.J.-based Novartis, is the first medicine approved to treat CIU since H1-antihistamines, according to the news release.
In 2003, Xolair was approved to treat persistent allergic asthma.
More Articles on FDA Approvals:
FDA Approves Neuraceq for Brain Imaging
FDA Approves Implantable Device for Certain Type of Hearing Loss
FDA Approves Apixaban for New Use
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
